Answers are grounded in this paper and cite their sources.
This study mainly analyzed the correlation between human pap-illomavirus infection (HPV) and vaginal microecological environment and ex-plored the effect of Lactobacillus vaginal capsule combined with recombinant human interferon α-2b gel on HPV infection. Five hundred patients who un-derwent a gynecological examination in our hospital from June 2021 to June 2023 were selected and divided into HPV-positive and HPV-negative groups. Relative to the HPV-negative group, the HPV-positive group presented a higher abnormal rate of Lactobacillus, catalase, cleanliness, neuraminidase and pro-line aminopeptidase (p<0.05) and a higher positive rate of bacterial vaginosis (BV) (p<0.05). Multivariate logistic regression analysis showed that catalase, proline aminopeptidase and BV were risk factors for HPV infection (p<0.05). In addition, 180 HPV-positive patients were randomly divided into a control group (CG) and an observation group (OG). The CG was given recombinant human interferon α-2b gel, and the OG was treated with recombinant human inter-feron α-2b gel plus a Lactobacillus vaginal capsule. Relative to the CG, the OG presented a higher total effective rate (p<0.05), lower inflammation (p<0.01), better immune function (p<0.01), and a higher proportion of grade II-III vagi-nal flora density and grade II-III vaginal flora diversity (p<0.001). Collectively, HPV is significantly correlated with the vaginal microecological environment, and catalase, proline aminopeptidase and BV were closely related to HPV infec-tion. In addition, Lactobacillus vaginal capsule plus recombinant human inter-feron α-2b gel has practical clinical efficacy, which can reduce inflammation, promote immune function, improve vaginal microecological environment, and is safe in the treatment of patients with HPV infection.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: